Ligand Enters into Worldwide OmniAb Partnership with Genagon Therapeutics

Represented Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) in connection with its worldwide OmniAb partnership with Genagon Therapeutics AB, a Sweden-based developer of bio-pharmaceutical products designed to increase response rates in immuno-oncology. Pursuant to the agreement, Ligand received an upfront payment and is eligible to receive development milestone payments as well as tiered royalties for each product that incorporates an OmniAb-derived antibody. 

Ligand is a biopharmaceutical company that focuses on developing and/or acquiring technologies that help pharmaceutical companies in discovering and creating medicines.